drugset
drugset / Trial / NCT04185051

A Study to Investigate the Effect of JNJ-67953964 on Gastric Mucosal Integrity in Healthy Male and Female Participants

NCT04185051 ↗

Phase 1 Completed 76 enrolled Janssen Research & Development, LLC
RandomizedParallel-groupDouble-blindOther

Summary

The main purpose of the study is to investigate the upper gastro-intestinal (GI)-related safety and tolerability in healthy participants by gastroscopy and gastric biopsies after treatment with 25 milligram (mg) JNJ-67953964 once daily (QD) over 4 weeks.

Timeline

Start
2019-12-17
Primary completion
2021-04-21
Completion
2021-05-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Aticaprant Small molecule 25 mg Oral

Indications

No indication recorded.